

# Per- and Polyfluoroalkyl Substances and Immune Function in Children

Carmen Messerlian, PhD  
Assistant Professor of Environmental Reproductive Epidemiology  
Departments of Epidemiology and Environmental Health  
Director of Scientific Early Life Environmental Health and Development Program



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

**I have no conflicts of interest to declare.**



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

PLAN

01  
BACKGROUND

03  
PFAS AND COMMON COLD in NHANES

02  
PFAS AND IMMUNE FUNCTION

04  
CONCLUSIONS



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

INTRODUCTION

Works to understand how the Environment impacts reproductive health from the very earliest stages of life – from the formation of gametes and embryos – to the birth of infants and throughout child health and development.

Our mission is to Use cutting-edge evidence to inform clinical practice, translate science into policy action, and implement prevention strategies to improve the health of mothers, fathers, and their children.



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH



## BACKGROUND

**Exposure Pathways**

Dietary ingestion: packaging, seafood, drinking water

Dust ingestion

Dermal absorption

Indoor air inhalation



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

## BACKGROUND

**Children have higher body burden of****PFAS**

Mouthing behaviors

Different body size to surface area and intake ratios


Placental transfer

Breastfeeding



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

## Early Childhood as a Critical Window for Immune System Maturation



The immune system gradually matures throughout childhood

Deviations during this early "training period" may have long-term consequences for immune system outcomes

Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015. doi: 10.1098/rspb.2014.3085.



## 02

### PFAS and Immune Function

Experimental and Epidemiologic Evidence



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH



### Experimental Studies in Rodents

Most studies focused on PFOS and PFOA.

Some studies for PFNA and PFDA

Very limited evidence for other congeners

#### *Immunotoxic effects*

- Decreased spleen and thymus weights
- Reduction in circulating immune cells
- Reduction in antibody levels
- Altered cytokine production

#### *Mode of action*

- Not elucidated.
- May involve NF- $\kappa$ B
- Upregulation of apoptotic genes in thymus and spleen
- Possible involvement of peroxisome proliferator-activated receptors (PPARs)



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

In their latest 2020 evaluation, the European Food Safety Authority (EFSA) selected immunotoxicity as the most critical health endpoint for risk assessment based on both animal and human evidence.



EFSA Panel on Contaminants in the Food Chain (EFSA CONTAM Panel). Schrenk et al. Risk to human health related to the presence of perfluoroalkyl substances in food. EFSA J. 2020 Sep 17;18(9):e06223. doi: 10.2903/j.efsa.2020.6223.

Table 20: Studies on immunological effects of PFASs in rodents

Species	Strain	Sex	Route	Duration (days)	PFAS	NOAEL (mg/kg per day)	LOAEL	NOAEC (ng/mL)	LOAEC	Immune treatment	Days before sacrifice	Immune endpoint (+)	Effect	Reference
Mouse	B6C3F1	Male	Gavage	28	PFOS	0.000166	0.00166	18	52	SRBC	5 days	PFCs	↓	Peden-Adams et al. (2008)
Mouse	B6C3F1	Female	Gavage	28	PFOS	0.00331	0.0166	123	666	SRBC	5 days	PFCs	↓	
Mouse	B6C3F1	Female	Gavage	21	PFOS	0.005	0.025	189	670	Influenza		Survival	↓	Garuge et al. (2009)
Mouse	B6C3F1	Male	Diet	28	PFOS	0.25	—	11,600	—	SRBC	5 days	Serum IgM, PFCs	—	Qiu et al. (2010)
Mouse	B6C3F1	Male	via dam, gavage	GD 1-17	PFOS	1	5	NR	NR	SRBC	4 days	PFCs	↓	Keil et al. (2008)
Mouse	B6C3F1	Female	via dam, gavage		PFOS	5	—	NR	—	SRBC	4 days	PFCs	—	
Mouse	C57BL/6	Male	Gavage	60	PFOS	0.0033	0.0833	674	7,132	SRBC	4 days	PFCs	↓	Dong et al. (2009)
Mouse	C57BL/6	Male	Gavage	60	PFOS	0.0167	0.0833	2,360	10,750	SRBC	7 days	Serum IgM	↓	Dong et al. (2011)
Mouse	C57BL/6	Male	Gavage	60	PFOS	0.0833	0.4167	8,210	24,530	None		TNF- $\alpha$ , IL-6	↑	Dong et al. (2012)
Mouse	C57BL/6	Male	Gavage	7	PFOS	—	5	—	110,460	SRBC	5 days	PFCs	↓	Zheng et al. (2009)
Mouse	C57BL/6	Male	Gavage	7	PFOS	—	5	—	97,250	None		Non-specific IgM	↓	Zheng et al. (2011)
Mouse	BALB/c	Female	Gavage	21	PFOS	—	20	—	NR	Ovalbumin	14 and 7 days (two injections)	Serum IgM	↓	Vetvicka and Vetvickova, (2013)
					PFOA	—	20	—	NR				↓	
Mouse	CD-1 (ICR)BR	Male	Gavage	29	PFPO	1	10	32,000	225,000	SRBC	5 days	Serum IgM	↓	Lovalletti et al. (2008)
Mouse	C57BL/6	Female	Gavage	15	PFOA	1.88	3.75	NR	74,913	SRBC	5 days	Serum IgM	↓	DeWitt et al. (2008)
Mouse	C57BL/6	Female	Water	15	PFOA	7.5	30	NR	NR	SRBC	5 days	Serum IgM	↓	DeWitt et al. (2016)
Rat	SD	Male	Diet	28	PFOS	—	0.14	470	950	None		Serum IgG1	↓	Lefebvre et al. (2008)

**Limitations of animal models:** Relevant toxicokinetic differences between rodents and humans

### Epidemiologic Evidence



#### Immunosuppression

- **Antibody level:** prenatal or childhood PFAS exposure is negatively associated with specific antibody levels in childhood (**Most robust evidence**)
- **Other laboratory markers of the immune function:** reduced C-reactive protein response, increased basophil counts among children
- **Immune morbidity:** increased risks of common cold, infections, upper and lower respiratory airway infections among children



#### Immuno-reactivity

- Some evidence suggesting association between PFAS and asthma, allergy, serum IgE levels





# 03

## PFAS AND COMMON COLD in NHANES

Methods and Results



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

PFAS AND COMMON COLD in NHANES-Methods



### National Health and Nutrition Examination Study (NHANES)

A national survey

Measures the health and nutritional status in the United States every two years

Involves questionnaire interview, physical examination, and specimen collection for environmental and biomarker measurements

**We included children aged 3 to 11 and adolescents aged 12-19 from the 2013-2014 cycle**

1/3 of the total number of children or adolescents in the cycle

2013-2014 is the only cycle where PFAS were measured in children aged 3-11 years



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH



## Methods

### Exposure

Serum concentrations of the following PFAS compounds: PFOA, PFOS, perfluorohexane sulfonic acid (PFHxS), perfluorononanoic acid (PFNA)

### Outcome

Common cold obtained by:

"Did your child have a head cold or chest cold that started during the previous 30 days?"

### Covariates

Age (continuous), sex (dichotomous), races (Non-Hispanic White, Non-Hispanic Black, Hispanic, Other), and income-poverty ratio (<1, -1< and <2, 2-<) which is the ratio of family income to poverty guidelines

Obtained from questionnaires



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH



### Statistical Analysis

**Multivariable logistic regression:** to estimate odds ratio (OR) and 95% confidence interval (CI) of common cold per doubling of the individual PFAS biomarker concentration, adjusting for covariates

Weighted by NHANES sampling weights

Further investigated effect modification by sex



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

**Probit Bayesian Kernel Machine Regression (BKMR):**

To assess the joint effect of the PFAS mixture on common cold

BKMR can account for correlations, non-linear associations and interactions within mixture

Allowed us to evaluate:

- 1) Individual dose-response relationships between each compound and common cold when holding other compounds in the mixture at their median concentrations
- 2) Joint effect of the mixture on common cold by comparing the estimate for common cold across quantiles of the total mixture PFAS concentrations to the estimate in the median concentration of total mixture



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

**Children**  
**3-11 years**



**N=517**  
Mean age 7

52% non-Hispanic white  
14% non-Hispanic black

Prevalence of common cold 23%

**Adolescents**  
**12-19 years**



**N=394**  
Mean age 16

55% non-Hispanic white  
15% non-Hispanic black

Prevalence of common cold 17%



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

### PFAS Biomarker Distribution

Biomarkers	3-11 years		12-19 years	
	Detection Rate	GM (ng/ml)	Detection Rate	GM (ng/ml)
PFOA	100%	1.90	100%	1.70
PFOS	100%	3.87	100%	3.62
PFHxS	99.81%	0.85	100%	1.29
PFNA	99.81%	0.80	100%	0.61



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

### Multivariate Model

Adjusted Odds Ratio of Common Cold per Doubling of Biomarker Concentrations

Biomarkers	3-11 years	12-19 years
PFOA	1.32 (0.83, 2.10)	1.18 (0.71, 1.97)
PFOS	1.06 (0.76, 1.48)	1.16 (0.76, 1.78)
PFHxS	1.31 (1.06, 1.62)	1.23 (0.96, 1.59)
PFNA	1.36 (1.03, 1.80)	0.68 (0.46, 1.00)

**Covariates:** Age (continuous), sex (dichotomous), races (Non-Hispanic White, Non-Hispanic Black, Hispanic, Other), and income-poverty ratio (<1, -1< and <2, 2-<) which is the ratio of family income to poverty guidelines



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

**Multivariate Model**

Adjusted Odds Ratio of Common Cold per Doubling of Biomarker Concentrations

Stratified by Sex

Biomarkers	3-11 years			12-19 years		
	Male	Female	Test of Heterogeneity p	Male	Female	Test of Heterogeneity p
PFOA	1.28 (0.71, 2.29)	1.43 (0.63, 3.25)	0.84	0.69 (0.32, 1.50)	1.55 (0.77, 3.10)	0.19
PFOS	1.03 (0.67, 1.58)	1.14 (0.65, 1.99)	0.65	0.76 (0.30, 1.90)	1.42 (0.89, 2.24)	0.54
PFHxS	1.61 (1.20, 2.18)	0.96 (0.67, 1.37)	<b>0.09</b>	1.14 (0.79, 1.63)	1.37 (0.94, 2.02)	0.54
PFNA	1.41 (0.99, 2.01)	1.27 (0.80, 2.01)	0.75	0.33 (0.15, 0.72)	0.96 (0.59, 1.56)	<b>0.03</b>


**Covariates:** Age (continuous), sex (dichotomous), races (Non-Hispanic White, Non-Hispanic Black, Hispanic, Other), and income-poverty ratio (<1, =1< and <2, ≥2<) which is the ratio of family income to poverty guidelines



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

**BKMR Model**

Univariate dose-response relationship between individual PFAS concentration and common cold estimate, holding all other PFAS concentrations at their median concentrations




**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH


## BKMR Model

Cumulative effect of the total PFAS concentration on common cold:  
Change in common cold estimate per 5<sup>th</sup> percentile increase/decrease from the median concentrations of all PFAS biomarkers

3-11 years



12-19 years



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH



## SUMMARY

Robust association for serum **PFHxS** concentration and increased odds of common cold among **children and adolescents**

Positive association between serum **PFNA** concentration and common cold in **children** while a possible negative association among adolescents.

A clear increasing trend of common cold estimate across quantiles of the concentration of the total PFAS **mixture** among **children**, but **not adolescents**



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH




# 04

## Conclusions



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

### Summary



Associations between PFAS and common cold most evident during childhood

**Early childhood may be a more critical period for PFAS-related immune effects** compared to adolescence

Adolescent PFAS exposure may be more prone to confounding by dietary, personal care product use, and other exposure sources or behaviors (e.g. smoking/alcohol)

## DISCUSSION

**Strengths**

Nationally representative sample

Childhood window of exposure

Long half-lives of PFAS counteracts cross-sectional design, making reverse causality less likely

Common cold as a marker of general immune system function

Mixture methodology

**Limitations**

Lack of data on confounders: breastfeeding and dietary intake (e.g. seafood consumption)

Self-reported outcome

Inability to account for prenatal PFAS of NHANES participants

Investigate four of the most important PFAS, exposed to dozens of congeners that were not accounted for - likely leads to underestimation of effect



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

**PFAS Lessons: Safety must be demonstrated before commercialization**

Grandjean P. Delayed discovery, dissemination, and decisions on intervention in environmental health: a case study on immunotoxicity of perfluorinated alkylate substances. Environ Health. 2018. doi: 10.1186/s12940-018-0405-y.

Mixtures, rather than isolated PFAS, may lead to immunosuppressive effects and increased susceptibility to common cold infections

The PFAS mixture effect was clearly evident in childhood, which represents one of the most critical windows of exposure for immune function

Although there is limited immunotoxicological data for PFNA and PFHx, our results suggest that these perfluorinated compounds are not safer than PFOA and PFOS



**HARVARD**  
**T.H. CHAN**  
SCHOOL OF PUBLIC HEALTH

## ACKNOWLEDGEMENTS

Yu Zhang

Vicente Mustieles

Yang Sun

Yixin Wang

Stelios Vagios

Preconception PFAS Exposure and Reproduction (PREPARE) Study  
R01ES031657 (PI: Messerlian)

NIEHS Program Officers

Antonia Calafat  
Centers for Disease Control and Prevention

Dr John Petrozza

Dr Irene Souter

Vincent Center for  
Reproductive Biology

Massachusetts General  
Hospital



## THANK YOU

Carmen Messerlian  
cmesser@hsph.harvard.edu



**SEED**  
Scientific Early Life  
Environmental Health &  
Development Program

THRIVE

